ArticleJournal of radiosurgery and SBRT2020
Optimal prescription isodose line in SBRT for lung tumor treatment with volumetric-modulated arc therapy.
Article in Journal of radiosurgery and SBRT, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.Journal of radiation research · 2026Article
- Margin reduction and optimal prescription isodose model for liver stereotactic radiotherapy with respiratory motion.Journal of applied clinical medical physics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is crucial to spare lung when treating early stage lung carcinoma with stereotactic body radiotherapy (SBRT) for minimizing the radiation induced toxicities, such as radiation pneumonitis and late fibrosis. A retrospective study was performed with a combination of approaches to determine the optimal range of prescription isodose line (P-IDL) within which lung tissue was best spared in SBRT plans with Volumetric-Modulated Arc Therapy (VMAT) and Monte-Carlo-like dose calculation algorithm. Twenty clinically-delivered SBRT lung plans were optimized using traditional LINAC MLC based approaches: an average P-IDL of (88.8 ± 0.5)% (the error bar of all the data is the 95% confidence interval (CI)). The plans were then re-optimized using a new combination of approaches with variation of P-IDL from 60% to 90% for each case. The combination of approaches included finding and utilizing an optimal P-IDL, implementing tuning ring structures internal and external to the target, as well as normal tissue objective and equivalent. The plans were evaluated with the following indexes: 1. R
Indexed as
Identifiers
33282469PMC7717096W3112661706What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.